文献速递淋巴瘤

嵌合抗原受体T细胞疗法治疗成人复发或难治性滤泡性淋巴瘤的成本效益

Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

该研究采用Markov模型,从美国支付方视角评估三线嵌合抗原受体(CAR)T细胞疗法与标准治疗在成人复发或难治性滤泡性淋巴瘤中的成本效益,以每质量调整生命年15万美元为支付意愿阈值。结果显示CAR T细胞策略成本为731682美元,标准治疗为458490美元,增量收益为1.50质量调整生命年,增量成本效益比为每质量调整生命年182127美元。作者认为在当前定价下,CAR T细胞疗法在未经选择的第三线滤泡性淋巴瘤患者中不太可能具有成本效益。

要点

  • 三线CAR T细胞疗法成本731682美元,标准治疗458490美元。
  • CAR T细胞疗法增量收益1.50质量调整生命年,增量成本效益比182127美元/质量调整生命年。
  • 模型对CAR T细胞缓解效用、三线标准治疗效用及CAR T细胞前期总成本最敏感。

核心结论

  • 在当前定价下,CAR T细胞疗法在未经选择的第三线滤泡性淋巴瘤患者中不太可能具有成本效益。

研究设计与样本

  • 研究采用Markov模型,从美国支付方视角、终身时间范围评估第三线CAR T细胞疗法与标准治疗在成人复发或难治性滤泡性淋巴瘤中的成本效益。
  • CAR T细胞疗法和标准治疗的进展率分别从ZUMA-5试验和LEO CReWE研究估计。

主要发现

  • 基础病例模型中,CAR T细胞策略成本为731682美元,标准治疗为458490美元。
  • CAR T细胞疗法与1.50质量调整生命年的增量临床获益相关,增量成本效益比为每质量调整生命年182127美元。
  • 模型对CAR T细胞疗法缓解效用、第三线标准治疗效用及CAR T细胞疗法前期总成本最敏感。

关键数值与推荐

  • 支付意愿阈值为每质量调整生命年150000美元。
  • CAR T细胞疗法定价为373000美元。
  • 美国食品药品监督管理局于2021年3月批准CAR T细胞疗法用于接受≥2线治疗后的复发或难治性滤泡性淋巴瘤患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021, the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) FL after ≥2 lines of therapy. Priced at $373 000, CAR T-cell therapy is potentially curative, and its cost-effectiveness compared with other modern R/R FL treatment strategies is unknown. We developed a Markov model to assess the cost-effectiveness of third-line CAR T-cell vs standard of care (SOC) therapies in adults with R/R FL. We estimated progression rates for patients receiving CAR T-cell and SOC therapies from the ZUMA-5 trial and the LEO CReWE study, respectively. We calculated costs, discounted life years, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) of CAR T-cell vs SOC therapies with a willingness-to-pay threshold of $150 000 per QALY. Our analysis was conducted from a US payer's perspective over a lifetime horizon. In our base-case model, the cost of the CAR T-cell strategy was $731 682 compared with $458 490 for SOC therapies. However, CAR T-cell therapy was associated with incremental clinical benefit of 1.50 QALYs, resulting in an ICER of $182 127 per QALY. Our model was most sensitive to the utilities associated with CAR T-cell therapy remission and third-line SOC therapies and to the total upfront CAR T-cell therapy cost. Under current pricing, CAR T-cell therapy is unlikely to be cost-effective in unselected patients with FL in the third-line setting. Both randomized clinical trials and longer term clinical follow-up can help clarify the benefits of CAR T-cell therapy and optimal sequencing in patients with FL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Potnis KC, Di M, Isufi I, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv. 2023. PMID: 36342852. doi:10.1182/bloodadvances.2022008097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。